Buy Relinquish‑M 62.5 mg/375 mg (Artemisinin/Piperaquine) – Effective Malaria Treatment

Relinquish‑M combines artemisinin 62.5 mg with piperaquine 375 mg, forming a WHO-recommended artemisinin-based combination therapy (ACT) for the treatment of uncomplicated Plasmodium falciparum and vivax malaria ([turn0search2], [turn0search18]). It is manufactured by Kachhela Medex Pvt. Ltd. in India and sold globally with prescription-based distribution ([turn0search5], [turn0search8]).

How It Works

Artemisinin derivatives rapidly reduce parasite biomass by generating free radicals in infected red blood cells. Piperaquine, as a longer-lasting partner drug, prevents recurrence by clearing residual parasites and offering post-treatment prophylaxis ([turn0search19], [turn0search17]).

Dosage & Administration

• Relinquish‑M is provided as a 6‑dose regimen over three days, taken orally—typically one or two tablets daily, depending on body weight, under physician guidance.
• Take with fatty food to enhance absorption. If vomiting occurs within 1–2 hours after dosing, consult a healthcare provider for dose repeat ([turn0search18], [turn0search9]).

Benefits

• Fast and effective clearance of malaria parasites with high cure rates in uncomplicated cases.
• World Health Organization–listed essential medication included among ACT options like dihydroartemisinin-piperaquine ([turn0search18]).
• Convenient blister packaging in strips of 4 tablets with international shipping support ([turn0search5], [turn0search6]).

Side Effects & Warnings

• Mild side effects may include nausea, headache, dizziness, and gastrointestinal symptoms.
• Piperaquine may prolong QT interval—avoid use with other QT-prolonging drugs or in patients with known cardiac conditions ([turn0search17]).

Precautions & Interactions

• Prescription-only. Not for malaria prevention or severe infections.
• Avoid in pregnancy (first trimester) unless clinically justified—use only under medical supervision.
• Check drug interactions with other QT prolonging or CYP-modulating medications.

Worldwide Shipping

Relinquish‑M ships globally with discreet packaging and full tracking. Delivery typically takes 6–15 business days; prescription required ([turn0search5], [turn0search2]).

📌 Frequently Asked Questions (FAQs)

1. What is Relinquish‑M used for?

It treats uncomplicated malaria (both P. falciparum and vivax) using WHO-recommended combination therapy artemisinin + piperaquine ([turn0search2], [turn0search18]).

2. How is the dosage structured?

Administered over 3 days (6 doses), typically once or twice daily based on weight—taken with a fatty meal for better absorption. If vomiting within 2 hours, repeat the dose once.

3. Are there any major side effects?

Generally well tolerated. Watch for gastrointestinal discomfort, dizziness. Serious QT prolongation risk exists; monitor ECG if used with other QT drugs ([turn0search17]).

4. Can it be used for malaria prophylaxis?

No—designed only for acute, uncomplicated malaria treatment. Not suitable for prevention.

5. Is it safe during pregnancy?

Relinquish‑M is not recommended in early pregnancy. If needed, use under medical supervision after risk assessment.